SIGMAR1 and melanoma: We employed two specific AAG8 antagonists in the micromolar range, the routinely used concentrations in vitro 17, for modeling the AAG8 antagonism and drug resistance in melanoma cells, though it is a higher dose comparing to current anti-tumor drugs 20.